Logo image of CWBR

COHBAR INC (CWBR) Stock Fundamental Analysis

NASDAQ:CWBR - Nasdaq - US19249J3077 - Common Stock - Currency: USD

0.761  -0.14 (-15.44%)

After market: 0.7345 -0.03 (-3.48%)

Fundamental Rating

2

Taking everything into account, CWBR scores 2 out of 10 in our fundamental rating. CWBR was compared to 563 industry peers in the Biotechnology industry. While CWBR seems to be doing ok healthwise, there are quite some concerns on its profitability. CWBR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CWBR has reported negative net income.
CWBR had a negative operating cash flow in the past year.
CWBR had negative earnings in each of the past 5 years.
In the past 5 years CWBR always reported negative operating cash flow.
CWBR Yearly Net Income VS EBIT VS OCF VS FCFCWBR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -5M -10M -15M

1.2 Ratios

Looking at the Return On Assets, with a value of -101.44%, CWBR is doing worse than 79.57% of the companies in the same industry.
CWBR has a Return On Equity of -133.58%. This is in the lower half of the industry: CWBR underperforms 64.45% of its industry peers.
Industry RankSector Rank
ROA -101.44%
ROE -133.58%
ROIC N/A
ROA(3y)-68.44%
ROA(5y)-73.98%
ROE(3y)-75.95%
ROE(5y)-95.1%
ROIC(3y)N/A
ROIC(5y)N/A
CWBR Yearly ROA, ROE, ROICCWBR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CWBR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CWBR Yearly Profit, Operating, Gross MarginsCWBR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022

More info and screens

6

2. Health

2.1 Basic Checks

CWBR has more shares outstanding than it did 1 year ago.
There is no outstanding debt for CWBR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CWBR Yearly Shares OutstandingCWBR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 500K 1M 1.5M 2M 2.5M
CWBR Yearly Total Debt VS Total AssetsCWBR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M 25M

2.2 Solvency

CWBR has an Altman-Z score of -13.68. This is a bad value and indicates that CWBR is not financially healthy and even has some risk of bankruptcy.
CWBR has a worse Altman-Z score (-13.68) than 84.22% of its industry peers.
There is no outstanding debt for CWBR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -13.68
ROIC/WACCN/A
WACCN/A
CWBR Yearly LT Debt VS Equity VS FCFCWBR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 4.16 indicates that CWBR has no problem at all paying its short term obligations.
CWBR has a Current ratio (4.16) which is comparable to the rest of the industry.
CWBR has a Quick Ratio of 4.16. This indicates that CWBR is financially healthy and has no problem in meeting its short term obligations.
CWBR has a Quick ratio (4.16) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.16
Quick Ratio 4.16
CWBR Yearly Current Assets VS Current LiabilitesCWBR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M 25M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 8.02% over the past year.
EPS 1Y (TTM)8.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-58.51%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-3.7%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CWBR Yearly EPS VS EstimatesCWBR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CWBR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CWBR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CWBR Price Earnings VS Forward Price EarningsCWBR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CWBR Per share dataCWBR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CWBR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COHBAR INC

NASDAQ:CWBR (11/28/2023, 8:00:00 PM)

After market: 0.7345 -0.03 (-3.48%)

0.761

-0.14 (-15.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2023-11-14/amc
Earnings (Next)03-07 2024-03-07/amc
Inst Owners6.24%
Inst Owner Change0%
Ins Owners238.68%
Ins Owner Change0%
Market Cap2.21M
Analysts43.33
Price Target18.36 (2312.61%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.23
P/tB 0.23
EV/EBITDA N/A
EPS(TTM)-4.36
EYN/A
EPS(NY)-4
Fwd EYN/A
FCF(TTM)-2.73
FCFYN/A
OCF(TTM)-2.73
OCFYN/A
SpS0
BVpS3.27
TBVpS3.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -101.44%
ROE -133.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-68.44%
ROA(5y)-73.98%
ROE(3y)-75.95%
ROE(5y)-95.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.16
Quick Ratio 4.16
Altman-Z -13.68
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)8.63%
Cap/Depr(5y)130.18%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-58.51%
EPS Next Y-3.7%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-7.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y41.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y40.94%
OCF growth 3YN/A
OCF growth 5YN/A